How should I manage a patient with a serum potassium of 5.2 mEq/L (mild hyperkalaemia) who has no electrocardiographic changes or symptoms?

Management of Potassium 5.2 mEq/L

For a patient with potassium 5.2 mEq/L without ECG changes or symptoms, focus on identifying and correcting reversible precipitating factors rather than initiating acute treatment, while ensuring continuation of any life-saving medications like RAAS inhibitors. 1

Initial Assessment

First, confirm this is true hyperkalemia and not pseudohyperkalemia from:

• Hemolysis during blood draw
• Repeated fist clenching during phlebotomy
• Delayed specimen processing
• Note that plasma potassium runs 0.1-0.4 mEq/L lower than serum 2

Obtain an ECG even without symptoms, as ECG changes may not correlate reliably with potassium levels 3. However, the absence of ECG changes at 5.2 mEq/L means you do not need emergent treatment with IV calcium, insulin/glucose, or beta-agonists 2.

Risk Stratification

This level (5.2 mEq/L) represents mild hyperkalemia where adverse cardiovascular outcomes can still manifest, particularly in patients with cardiorenal disease 1. Determine if this is:

• First episode: May be transient and reversible
• Recurrent hyperkalemia: Defined as >1 episode of K+ >5.0 mEq/L per year, requiring different management 1

Identify and Address Reversible Factors

The priority is correcting precipitating causes 1:

• Medications: Review NSAIDs, potassium-sparing diuretics, trimethoprim, heparin, calcineurin inhibitors
• Metabolic acidosis: Check and correct if present
• Volume status: Optimize diuretic therapy if hypervolemic and non-oliguric 2
• Dietary intake: Focus on reducing non-plant sources of potassium rather than blanket dietary restriction, as evidence for strict dietary potassium restriction is lacking 4

Critical Pitfall: Do NOT Stop RAAS Inhibitors

If the patient is on ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists for heart failure or proteinuric kidney disease, do not discontinue or down-titrate these medications 1, 2. Withdrawal of RAAS inhibitors is associated with:

• Increased mortality
• More hospitalizations for heart failure
• Progression to end-stage kidney disease 1

Instead, manage the hyperkalemia through other measures to maintain these life-saving therapies 1.

Treatment Algorithm for K+ 5.2 mEq/L

1. Repeat potassium measurement within 7-10 days to determine if chronic or transient 2

2. If first episode and reversible cause identified: Address the cause and monitor

3. If recurrent or no reversible cause: Consider potassium binder therapy 1

   • Newer agents (patiromer or sodium zirconium cyclosilicate) are preferred over sodium polystyrene sulfonate due to better safety profile 5, 6
   • These allow optimization of RAAS inhibitor dosing 2, 6
   • Treatment is likely indefinite unless the underlying cause can be reversed 1

4. Following normalization with a potassium binder: Additional monitoring beyond routine comorbidity monitoring is not necessary 1

Monitoring Strategy

Check potassium levels:

• Within 1 week if on RAAS inhibitors or after dose escalation 2
• More frequently if multiple risk factors present (CKD, diabetes, heart failure, history of hyperkalemia) 2
• The goal is to maintain potassium in normal range to prevent the increased morbidity and mortality associated with even mild chronic hyperkalemia 1, 6

The most recent European consensus (2025) emphasizes that normalizing potassium should not come at the expense of discontinuing guideline-directed medical therapy for underlying conditions 1. This represents a paradigm shift from older practices of stopping RAAS inhibitors when hyperkalemia develops.